[1]	(2004). Insulin synthesis and secretion. (Zugriff vom 07.08.2004)
	http://arbl.cvmbs.colostate.edu/hbooks/pathphys/endocrine/pancreas/insulin.html

[2]	(2004). Physiologic effects of insulin. (Zugriff vom 08.07.2004)
	http://arbl.cvmbs.colostate.edu/hbooks/pathphys/endocrine/pancreas/insulin_phys.html

[3]	Nationales Referenzzentrum (NRZ) für Surveillance von nosokomialen Infektionen (2003). Definition nosokomialer Infektionen (CDC-Definitionen). 4.  Auflage,  Robert-Koch-Institut Berlin.

[4]	Szabo, Z., Hakanson, E., Maros, T., Svedjeholm, R. (2003). High-dose glucose-insulin-potassium after cardiac surgery: a retrospective analysis of clinical safety issues. Acta Anaesthesiol Scand 47 (4), S. 383-390

[5]	Karow, T., Lang-Roth, R. (2004). Orale Antidiabetika.
	Aus: Allgemeine und spezielle Pharmakologie und Toxikologie, Auflage, S. 642-645, 

[6]	Shulman, G.I. (1999). Cellular mechanisms of insulin resistance in humans. Am J Cardiol 84 (1A), S. 3J-10J

[7]	Gore, D.C., Wolf, S.E., Sanford, A.P., Herndon, D.N., Wolfe, R.R. (2004). Extremity hyperinsulinemia stimulates muscle protein synthesis in severely injured patients. Am J Physiol Endocrinol Metab 286 (4), S. E529-534

[8]	Jeschke, M.G. (2003). Intensivierte Insulintherapie bei Sepsis. Anaesthesist 52 Suppl 1 S. S20-23

[9]	Weigand, M.A., Bardenheuer, H.J., Bottiger, B.W. (2003). Klinisches Management bei Patienten mit Sepsis. Anaesthesist 52 (1), S. 3-22

[10]	Bates, D.W. (2002). Unexpected hypoglycemia in a critically ill patient. Ann Intern Med 137 (2), S. 110-116

[11]	Lewis, K.S., Kane-Gill, S.L., Bobek, M.B., Dasta, J.F. (2004). Intensive insulin therapy for critically ill patients. Ann Pharmacother 38 (7-8), S. 1243-1251

[12]	Carlson, G.L. (2004). Hunterian Lecture: Insulin resistance in human sepsis: implications for the nutritional and metabolic care of the critically ill surgical patient. Ann R Coll Surg Engl 86 (2), S. 75-81

[13]	Bessey, P.Q., Lowe, K.A. (1993). Early hormonal changes affect the catabolic response to trauma. Ann Surg 218 (4), S. 476-489; discussion 489-491

[14]	Essen, P., Thorell, A., McNurlan, M.A., Anderson, S., Ljungqvist, O., Wernerman, J., Garlick, P.J. (1995). Laparoscopic cholecystectomy does not prevent the postoperative protein catabolic response in muscle. Ann Surg 222 (1), S. 36-42

[15]	Jeschke, M.G., Klein, D., Herndon, D.N. (2004). Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 239 (4), S. 553-560

[16]	Klein, D., Schubert, T., Horch, R.E., Jauch, K.W., Jeschke, M.G. (2004). Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma. Ann Surg 240 (2), S. 340-349

[17]	Mizock, B.A. (2001). Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 15 (4), S. 533-551

[18]	Löffler, G. (1998). Insulin: Struktur, Biosynthese und Sekretion.
	Aus: Biochemie und Pathobiochemie, 6.  Auflage, S. 788-793, Springer Verlag Berlin

[19]	Thorell, A., Efendic, S., Gutniak, M., Haggmark, T., Ljungqvist, O. (1994). Insulin resistance after abdominal surgery. Br J Surg 81 (1), S. 59-63

[20]	Jauch, K.W. (1997). Chirurgischer Metabolismus. Chirurg 68 (6), S. 551-558

[21]	Malmberg, K., Norhammar, A., Wedel, H., Ryden, L. (1999). Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 99 (20), S. 2626-2632

[22]	Johan Groeneveld, A.B., Beishuizen, A., Visser, F.C. (2002). Insulin: a wonder drug in the critically ill? Crit Care 6 (2), S. 102-105

[23]	McCowen, K.C., Malhotra, A., Bistrian, B.R. (2001). Stress-induced hyperglycemia. Crit Care Clin 17 (1), S. 107-124

[24]	Van den Berghe, G. (2002). Neuroendocrine pathobiology of chronic critical illness. Crit Care Clin 18 (3), S. 509-528

[25]	Bertolini, G., Latronico, N., Brazzi, L., Radrizzani, D. (2003). Insulin dose or glycemic control for the critically ill? Crit Care Med 31 (10), S. 2565-2566; author reply 2566

[26]	Bone, R.C. (1996). Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24 (1), S. 163-172

[27]	Coursin, D.B., Connery, L.E., Ketzler, J.T. (2004). Perioperative diabetic and hyperglycemic management issues. Crit Care Med 32 (4 Suppl), S. S116-125

[28]	Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E. (1985). APACHE II: a severity of disease classification system. Crit Care Med 13 (10), S. 818-829

[29]	Shipman, J., Guy, J., Abumrad, N.N. (2003). Repair of metabolic processes. Crit Care Med 31 (8 Suppl), S. S512-517

[30]	Van den Berghe, G., Wouters, P.J., Bouillon, R., Weekers, F., Verwaest, C., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P. (2003). Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31 (2), S. 359-366

[31]	Solano, T., Totaro, R. (2004). Insulin therapy in critically ill patients. Curr Opin Clin Nutr Metab Care 7 (2), S. 199-205

[32]	Das, U.N. (2003). Insulin: an endogenous cardioprotector. Curr Opin Crit Care 9 (5), S. 375-383

[33]	Morris, A.H. (2003). Treatment algorithms and protocolized care. Curr Opin Crit Care 9 (3), S. 236-240

[34]	Patel, G.P., Gurka, D.P., Balk, R.A. (2003). New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care 9 (5), S. 390-396

[35]	Trager, K., DeBacker, D., Radermacher, P. (2003). Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9 (4), S. 271-278

[36]	Heinemann, L., Chantelau, E.A., Starke, A.A. (1992). Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin. Diabete Metab 18 (1), S. 21-24

[37]	Heinemann, L., Richter, B. (1993). Clinical pharmacology of human insulin. Diabetes Care 16 Suppl 3 S. 90-100

[38]	Schranz, D.B., Lernmark, A. (1998). Immunology in diabetes: an update. Diabetes Metab Rev 14 (1), S. 3-29

[39]	Hepp, K.D., Häring, H.U. (2003). Einführung in die Biochemie und Pathophysiologie des Stoffwechsels.
	Aus: Diabetologie in Klinik und Praxis, 5.  Auflage, S. 1-42, Thieme Verlag Stuttgart

[40]	Mesotten, D., Van den Berghe, G. (2003). Clinical potential of insulin therapy in critically ill patients. Drugs 63 (7), S. 625-636

[41]	Jeschke, M.G., Klein, D., Bolder, U., Einspanier, R. (2004). Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology S. 

[42]	Ma, Y., Toth, B., Keeton, A.B., Holland, L.T., Chaudry, I.H., Messina, J.L. (2004). Mechanisms of Hemorrhage-induced Hepatic Insulin Resistance: Role of Tumor Necrosis Factor alpha. Endocrinology S. 

[43]	Powers, A.C. (2004) Diabetes mellitus. Aus: Harrison's internal medicine, Kapitel 333, The McGraw-Hill Companies
	http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch333/ch333_p01.html

[44]	Polonsky, K.S., Sturis, J., Van Cauter, E. (1998). Temporal profiles and clinical significance of pulsatile insulin secretion. Horm Res 49 (3-4), S. 178-184

[45]	Hartl, W.H., Jauch, K.W. (1994). Postaggressionsstoffwechsel: Versuch einer Standortbestimmung. Infusionsther Transfusionsmed 21 (1), S. 30-40

[46]	Kanji, S., Singh, A., Tierney, M., Meggison, H., McIntyre, L., Hebert, P.C. (2004). Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults. Intensive Care Med 30 (5), S. 804-810

[47]	Marik, P.E., Raghavan, M. (2004). Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30 (5), S. 748-756

[48]	McMullin, J., Brozek, J., Jaeschke, R., Hamielec, C., Dhingra, V., Rocker, G., Freitag, A., Gibson, J., Cook, D. (2004). Glycemic control in the ICU: a multicenter survey. Intensive Care Med 30 (5), S. 798-803

[49]	Hansen, T.K., Thiel, S., Wouters, P.J., Christiansen, J.S., Van den Berghe, G. (2003). Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88 (3), S. 1082-1088

[50]	Mesotten, D., Wouters, P.J., Peeters, R.P., Hardman, K.V., Holly, J.M., Baxter, R.C., Van den Berghe, G. (2004). Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. J Clin Endocrinol Metab 89 (7), S. 3105-3113

[51]	Mesotten, D., Swinnen, J.V., Vanderhoydonc, F., Wouters, P.J., Van den Berghe, G. (2004). Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 89 (1), S. 219-226

[52]	Tritos, N.A., Mantzoros, C.S. (1998). Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 83 (9), S. 3025-3030

[53]	Umpierrez, G.E., Isaacs, S.D., Bazargan, N., You, X., Thaler, L.M., Kitabchi, A.E. (2002). Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87 (3), S. 978-982

[54]	Virkamaki, A., Ueki, K., Kahn, C.R. (1999). Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103 (7), S. 931-943

[55]	Nylen, E.S., Muller, B. (2004). Endocrine changes in critical illness. J Intensive Care Med 19 (2), S. 67-82

[56]	Andersen, S.K., Gjedsted, J., Christiansen, C., Tonnesen, E. (2004). The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol 75 (3), S. 413-421

[57]	Finney, S.J., Zekveld, C., Elia, A., Evans, T.W. (2003). Glucose control and mortality in critically ill patients. Jama 290 (15), S. 2041-2047

[58]	Montori, V.M., Bistrian, B.R., McMahon, M.M. (2002). Hyperglycemia in acutely ill patients. Jama 288 (17), S. 2167-2169

[59]	Van den Berghe, G., Bouillon, R. (2004). Optimal control of glycemia among critically ill patients. Jama 291 (10), S. 1198-1199

[60]	Capes, S.E., Hunt, D., Malmberg, K., Gerstein, H.C. (2000). Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355 (9206), S. 773-778

[61]	Voigt, K. (2003). Die Insulinsekretion wird durch Glucose stimuliert.
	Aus: Lehrbuch der Physiologie, Herausgeber: S. Silbernagl, R. Klinke, 4.  Auflage, S. 486-488, Thieme Verlag

[62]	Krinsley, J.S. (2004). Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79 (8), S. 992-1000

[63]	Van den Berghe, G. (2004). Tight blood glucose control with insulin in "real-life" intensive care. Mayo Clin Proc 79 (8), S. 977-978

[64]	Heise, T., Heinemann, L., Starke, A.A. (1998). Simulated postaggression metabolism in healthy subjects: metabolic changes and insulin resistance. Metabolism 47 (10), S. 1263-1268

[65]	Peraldi, P., Spiegelman, B. (1998). TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 182 (1-2), S. 169-175

[66]	Jeschke, M.G., Einspanier, R., Klein, D., Jauch, K.W. (2002). Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med 8 (8), S. 443-450

[67]	(2000). Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342 (18), S. 1301-1308

[68]	Cline, G.W., Petersen, K.F., Krssak, M., Shen, J., Hundal, R.S., Trajanoski, Z., Inzucchi, S., Dresner, A., Rothman, D.L., Shulman, G.I. (1999). Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341 (4), S. 240-246

[69]	Evans, T.W. (2001). Hemodynamic and metabolic therapy in critically ill patients. N Engl J Med 345 (19), S. 1417-1418

[70]	Hirsch, I.B., Coviello, A. (2002). Intensive insulin therapy in critically ill patients. N Engl J Med 346 (20), S. 1586-1588; author reply 1586-1588

[71]	Shepherd, P.R., Kahn, B.B. (1999). Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med 341 (4), S. 248-257

[72]	van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., Bouillon, R. (2001). Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (19), S. 1359-1367

[73]	Brady, M.J., Saltiel, A.R. (1999) Insulin and Glucagon. Aus: Nature Encyclopedia of Life Sciences, 2004, Nature Publishing Group
	http://www.els.net

[74]	Najjar, S. (2000) Insulin action: molecular basis of Diabetes. Aus: Nature Encyclopedia of Life Sciences, 2004, Nature Publishing Group
	http://www.els.net

[75]	Lill, N. (2001). Insulinformulierungen. Pharm Unserer Zeit 30 (1), S. 56-62

[76]	Zündorf, I., Dingermann, T. (2001). Vom Rinder-, Schweine-, Pferdeinsulin zum Humaninsulin: Die biotechnische und gentechnische Insulinherstellung. Pharm Unserer Zeit 30 (1), S. 27-32

[77]	Mizock, B.A. (2003). Blood glucose management during critical illness. Rev Endocr Metab Disord 4 (2), S. 187-194

[78]	Bonville, D.A., Parker, T.S., Levine, D.M., Gordon, B.R., Hydo, L.J., Eachempati, S.R., Barie, P.S. (2004). The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg Infect (Larchmt) 5 (1), S. 39-49

[79]	Plank, L.D., Hill, G.L. (2000). Sequential metabolic changes following induction of systemic inflammatory response in patients with severe sepsis or major blunt trauma. World J Surg 24 (6), S. 630-638

[80]	Jauch, K.W., Kroner, G., Hermann, A., Inthorn, D., Hartl, W., Gunther, B. (1995). Postoperative Infusionstherapie: Elektrolytlösung im Vergleich zu hypokalorischen Glukose- bzw. Zuckeraustausch-Aminosäurenlösungen. Zentralbl Chir 120 (9), S. 682-688